Total Funding
78
68
Total FundingSeries A raised
Growth Score
-14 pts
Heat Score
6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
13680
Avanzanite Bioscience enhances access to orphan drugs in Europe, partnering with pharma for rare disease treatments.
- Mark Bechter: Senior Vice President of Medical AffairsPast Role: Kiniksa Pharmaceuticals, VP of Medical Operations and Patient Advocacy
- Adam Plich: Founder and CEOPast Role: Teva Pharmaceuticals, Vice President and Head of Pricing and European Market Access
About the Company
Avanzanite Bioscience focuses on enhancing access to medicines for rare diseases in Europe. It operates as a commercial-stage enterprise, partnering with pharmaceutical companies like Advicenne and SIFI to facilitate the distribution and commercialization of orphan drugs. Avanzanite's collaborations extend across several European countries,
including Ireland, Cyprus, Malta, Germany, and Austria, aiming to address the complexities and costs associated with the orphan drug market. The company's efforts are directed towards redefining the orphan drug landscape and unlocking new possibilities for patients suffering from rare diseases.
